Your browser doesn't support javascript.
loading
Optimization of Enzymatic and Chemical Decellularization of Native Porcine Heart Valves for the Generation of Decellularized Xenografts.
Saeid Nia, Monireh; Floder, Lena Maria; Seiler, Jette Anika; Puehler, Thomas; Pommert, Nina Sophie; Berndt, Rouven; Meier, David; Sellers, Stephanie L; Sathananthan, Janarthanan; Zhang, Xiling; Hasler, Mario; Gorb, Stanislav N; Warnecke, Gregor; Lutter, Georg.
Afiliação
  • Saeid Nia M; Department of Cardiac Surgery, University Hospital Schleswig-Holstein (UKSH), 24105 Kiel, Germany.
  • Floder LM; DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, 69120 Hamburg, Germany.
  • Seiler JA; Department of Cardiac Surgery, University Hospital Schleswig-Holstein (UKSH), 24105 Kiel, Germany.
  • Puehler T; Department of Cardiac Surgery, University Hospital Schleswig-Holstein (UKSH), 24105 Kiel, Germany.
  • Pommert NS; DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, 69120 Hamburg, Germany.
  • Berndt R; DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, 69120 Hamburg, Germany.
  • Meier D; Department of Cardiac Surgery, University Hospital Schleswig-Holstein (UKSH), 23562 Lübeck, Germany.
  • Sellers SL; Department of Cardiac Surgery, University Hospital Schleswig-Holstein (UKSH), 24105 Kiel, Germany.
  • Sathananthan J; DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, 69120 Hamburg, Germany.
  • Zhang X; Clinic of Vascular and Endovascular Surgery, University Hospital Schleswig-Holstein (UKSH), 24105 Kiel, Germany.
  • Hasler M; Department of Cardiology, Lausanne University Hospital and University of Lausanne, 1015 Lausanne, Switzerland.
  • Gorb SN; Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
  • Warnecke G; Cardiovascular Translational Laboratory, Providence Research & Centre for Heart Lung Innovation, Vancouver, BC V6Z 1Y6, Canada.
  • Lutter G; Centre for Heart Valve Innovation, St. Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada.
Int J Mol Sci ; 25(7)2024 Apr 04.
Article em En | MEDLINE | ID: mdl-38612836
ABSTRACT
One of the most important medical interventions for individuals with heart valvular disease is heart valve replacement, which is not without substantial challenges, particularly for pediatric patients. Due to their biological properties and biocompatibility, natural tissue-originated scaffolds derived from human or animal sources are one type of scaffold that is widely used in tissue engineering. However, they are known for their high potential for immunogenicity. Being free of cells and genetic material, decellularized xenografts, consequently, have low immunogenicity and, thus, are expected to be tolerated by the recipient's immune system. The scaffold ultrastructure and ECM composition can be affected by cell removal agents. Therefore, applying an appropriate method that preserves intact the structure of the ECM plays a critical role in the final result. So far, there has not been an effective decellularization technique that preserves the integrity of the heart valve's ultrastructure while securing the least amount of genetic material left. This study demonstrates a new protocol with untraceable cells and residual DNA, thereby maximally reducing any chance of immunogenicity. The mechanical and biochemical properties of the ECM resemble those of native heart valves. Results from this study strongly indicate that different critical factors, such as ionic detergent omission, the substitution of Triton X-100 with Tergitol, and using a lower concentration of trypsin and a higher concentration of DNase and RNase, play a significant role in maintaining intact the ultrastructure and function of the ECM.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bioprótese / Próteses Valvulares Cardíacas Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bioprótese / Próteses Valvulares Cardíacas Idioma: En Ano de publicação: 2024 Tipo de documento: Article